Purple orange book difference?

What are the “Orange Book” and “Purple Book”?

In the U.S., the FDA maintains two different drug reference systems that are often confused:

- Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations): lists approved drug products and provides information tied to generic substitution and whether products are considered therapeutically equivalent.
- Purple Book (Drugs for Rare Diseases and Related Designations): lists drugs designated for rare diseases (rare disease/small patient populations) and includes related designation and status information.

These books track different things: the Orange Book focuses on approved products and therapeutic equivalence, while the Purple Book focuses on rare-disease drug designation.

How do they differ in what they list?

Orange Book lists

• Approved drug products (typically by active ingredient, dosage form, strength)
  
• Applications associated with those products
  
• Therapeutic equivalence evaluations used to support generic substitution decisions
  
  

Purple Book lists

• Drugs that have received rare disease designation
  
• Information about the rare disease designation and related regulatory history
  
  

Why would someone look at the Orange Book instead of the Purple Book (or vice versa)?

• If you are trying to figure out whether a generic can be substituted for a brand-name product, people usually start with the Orange Book because it includes therapeutic equivalence evaluations.
  
• If you are researching rare disease drug status, designation history, or whether a specific therapy is recognized for rare disease purposes, people usually use the Purple Book.
  
  

Does one book include patent/ exclusivity details?

Neither book is the same thing as a full patent database, but:
- The Orange Book is commonly used as the starting point for related patent and exclusivity context because it’s tied to approved products.
- The Purple Book is centered on rare disease designation, not therapeutic equivalence.

For patent-focused research tied to branded drugs, DrugPatentWatch.com is a commonly used resource and can help when you want to go beyond FDA listing pages: DrugPatentWatch.com.

Quick example: what “difference” you’ll notice in practice

• In the Orange Book, you’ll see product-level approval and equivalence information (useful for substitution).
  
• In the Purple Book, you’ll see whether a drug is tied to a rare disease designation (useful for rare-disease status and designation research).
  
  

Sources

1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (FDA Orange Book)
   
2. https://www.fda.gov/industry/designating-and-appropriately-marketing-drugs-rare-diseases-and-related-terms/purple-book (FDA Purple Book)
   
3. https://www.drugpatentwatch.com/ (DrugPatentWatch.com)